IQV

$IQV

IQVIA Holdings Inc.

Health information technology and clinical research services.

Healthcare
$259.20
-5.53 (-2.09%)
Day Range$257.87 - $264.07
Prev Close$264.73

IQV key facts as of November 14, 2026

Latest AI research report
IQV Stock: Growth, Valuation and Risks (as of November 14, 2026)
StockAlpha report sentiment
Bullish (as of November 14, 2026)
Analyst consensus
Strong Buy (2 Strong Buy, 16 Buy, 2 Hold, 0 Sell, 0 Strong Sell) (as of November 1, 2026)
Analyst price target
$291.33 mean (range $240.00 to $346.00) (as of November 17, 2026)
Sector
Healthcare
Analyst Rating
Strong Buy
18 Buy / 2 Hold / 0 Sell
Price Target
$291.33
12.4% upside
Subscribers
0
Tracking this ticker
Latest Report

Analysis from Nov 14, 2026

BULLISH

IQV Stock: Growth, Valuation and Risks

IQVIA reported stronger-than-expected third-quarter earnings and rising clinical bookings, while analysts remain broadly positive. The shares have advanced sharply in recent months, leaving valuation, debt and execution risks important to weigh alongside growth prospects.

Nov 14, 2026

IQV FAQ

What is StockAlpha's latest view on IQV?

StockAlpha's latest AI research report on IQVIA Holdings Inc. (IQV), "IQV Stock: Growth, Valuation and Risks", was published on November 14, 2026 and rates the overall sentiment as bullish. IQVIA reported stronger-than-expected third-quarter earnings and rising clinical bookings, while analysts remain broadly positive. The shares have advanced sharply in recent months, leaving valuation, debt and execution risks important to weigh alongside growth prospects.

When was the IQV research last updated?

The most recent IQV report was published on November 14, 2026.

What do analysts expect for IQV?

As of November 1, 2026, the analyst consensus on IQV is Strong Buy (2 Strong Buy, 16 Buy, 2 Hold, 0 Sell, 0 Strong Sell). As of November 17, 2026, the analyst price target is $291.33 mean (range $240.00 to $346.00).

Is this IQV research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring